Life Science Future – MedTech Speakers
Learn more about the keynote speakers featured at
Life Sciences Future – MedTech 2020.
DSM Biomedical | 11:15 am – 11:35 am Friday, July 17
DSM Biomedical is the world’s unrivaled biomaterials expert and a committed partner driving sustainable innovation in healthcare. For 30 years, DSM has been at the forefront of biomaterial science and process innovation — the go-to resource for the world’s leading medical device and pharmaceutical companies. DSM is a strategic partner with an approach driven not only by market dynamics, but the unique needs of every customer. A partnership with us means access to biomaterial expertise and the backing of the broader DSM offering. We bring our customers an unparalleled breadth of product portfolios, proprietary manufacturing and processing capabilities, world-class IP, and extensive regulatory experience and expertise. DSM’s solutions and support are recognized for quality, reliability and performance in multiple markets. In 50 countries and 6 continents, benefiting millions of patients annually, the breadth of DSM’s global network is unmatched. Learn more at www.dsm.com/medical.
Vice President, Global Marketing and Sales, DSM Biomedical
Eric Shelton leads the sales and marketing operations of DSM Biomedical’s global business.
Mr. Shelton joined DSM from Nypro Healthcare, where he led their business development efforts in expansion of sales and services to major and emerging pharmaceutical and biotech companies. Before joining Nypro, Eric was the Executive Vice President, Global Sales & Marketing at SteriPack Group and held other leadership positions at Smith & Nephew, Phillips-Medisize and BASF. Eric is a highly accomplished senior leader who excels at analyzing lucrative global operational needs, identifying multimillion-dollar growth opportunities, defining methods for capturing new customers and retaining existing clientele, and attaining competitive market leverage.
Crohn’s & Colitis Foundation | 11:50 am – 12:10 pm Thursday, July 16
The Crohn’s & Colitis Foundation is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life of children and adults affected by these diseases. Since our founding in 1967, the Foundation has played a role in every major breakthrough in IBD research. We have invested more than $350 million into finding the causes, treatments, and cures for Crohn’s disease and ulcerative colitis. And we won’t stop until we realize our vision of a future free from Crohn’s and colitis.
The Foundation has been a leader in inflammatory bowel disease (IBD) research since our founding more than 50 years ago. We fund cutting-edge research studies and clinical trials at major medical institutions, and finance underdeveloped areas of research. We enthusiastically nurture investigators in the early stages of their career to help build the next generation of IBD researchers.
Gerard Honig, PhD
Associate Director of Research Innovation, Crohn's & Colitis Foundation
Speaker details coming soon.
Johnson & Johnson Innovation | 11:40 am – 12:00 pm Wednesday, July 15
Company description coming soon.
Ibraheem Badejo, Ph.D
Senior Director - New Ventures (Med Devices), Johnson & Johnson Innovation Center, Boston
Ibraheem (Ib) leverages his expertise in smart materials and biomaterials to support the medical device sector of Johnson & Johnson. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by Johnson & Johnson in 2005). Ib has held various positions at Bayer, North Carolina State University, and the College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.
During his career, Ibraheem has led teams in the development of commercialized biomaterials-based products and new technology / products licensed or acquired. Ib received his PhD in organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. Ib received the Science Alumni Award, Avila University in 2014. Ib is also the recipient of 24 US patents, he’s also well published in many peer review journals.
About OraSure Technologies
OraSure Technologies, Inc. (NASDAQ: OSUR) empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand) and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers.
President and Chief Executive Officer, OraSure Technologies, Inc.
OraSure Technologies – Company Reverse Pitch | 11:15 am – 11:35 am Thursday, July 16
Steve Tang became President & CEO of OraSure Technologies, Inc. (NASDAQ: OSUR) on April 1, 2018. Dr. Tang previously served as Chairman of the Board of Directors (2016-2018) and was first elected to the Board in 2011. Prior to April 2018, Dr. Tang served as President and CEO of the University City Science Center, the nation’s first and largest urban research park, from 2008-2018. During that decade, Tang initiated, led, and implemented a strategic plan designed to transform the Science Center from a traditional real-estate focused research park to an innovation powerhouse. From 2005-2008, he was a senior executive with Olympus America, including leading their Life Science Group of business. Prior to that, he was an energy technology entrepreneur and a senior executive at two leading global management consulting firms.
Company details coming soon.
Shawn Patrick O’Brien
CEO and Director of Genomind Inc.
Genomind Inc. – Company Reverse Pitch | 10:30 am – 10:50 am Wednesday, July 15
Shawn currently serves as the CEO and Director of Genomind Inc., a private personalized mental health business based in King of Prussia, which improves the lives of many around the globe through insights provided from its world class genetic lab and medical team.
A biotech and big pharma executive leader with over 35 years’ experience in building highly successful global enterprises. Shawn has extensive international experience in business development, marketing, selling, licensing, researching & developing both small and large molecules, with over 7 multi-Billion dollar product launches.
Since leaving big pharma 15 years ago, Shawn has been a serial entrepreneur leading 4 biotech companies before his current role at Genomind. In addition he has broad healthcare provider experience in USA, UK and Canada.
Shawn is the Chairman of Alto Pharma, Co-Chair of the Hubert Schoemaker Classic, Advisory Board member of both; The Greater Philadelphia Life Sciences Congress and Life Sciences Cares Philadelphia.
About Boston Scientific
Company description coming soon.
Senior Vice President, Corporate Strategy and Business Development, Boston Scientific
Boston Scientific – Company Reverse Pitch | 10:50 am – 11:10 am Friday, July 17
Charlie currently serves as Senior Vice President, Corporate Strategy and Business Development for Boston Scientific. He joined the company in 2010 and his team is responsible for corporate strategic planning as well as coordinating the identification, assessment and execution of business development transactions including acquisitions, VC/minority investments, divestitures, licensing deals, co-development agreements and joint ventures. Boston Scientific has been amongst the most active investors in medical technology over the past 10 years, having completed over 35 acquisitions across size ranges from sub $10 million to several $ billions, as well as growing our venture capital portfolio to over 40 investments across strategic areas of interest. Prior to Boston Scientific, Charlie spent 16 years in investment banking at Credit Suisse, DLJ and BT Alex Brown – in New York, Chicago and Paris. Charlie grew up in France and attended college at Princeton University where he received a Bachelor of Arts in Economics.
Questions about the event? Please contact email@example.com.